COSCIENS Biopharma Earnings Estimate
COSCIENS Biopharma Earnings per Share Projection vs Actual
About COSCIENS Biopharma Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of COSCIENS Biopharma earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current COSCIENS Biopharma estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as COSCIENS Biopharma fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -13.9 M | -14.6 M | |
| Earnings Yield | (2.46) | (2.34) | |
| Price Earnings Ratio | (0.42) | (0.44) |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in COSCIENS Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private. For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is there potential for Biotechnology market expansion? Will COSCIENS introduce new products? Factors like these will boost the valuation of COSCIENS Biopharma. Projected growth potential of COSCIENS fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about COSCIENS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.54) | Revenue Per Share | Quarterly Revenue Growth 0.176 | Return On Assets | Return On Equity |
Understanding COSCIENS Biopharma requires distinguishing between market price and book value, where the latter reflects COSCIENS's accounting equity. The concept of intrinsic value - what COSCIENS Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push COSCIENS Biopharma's price substantially above or below its fundamental value.
It's important to distinguish between COSCIENS Biopharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding COSCIENS Biopharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, COSCIENS Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.